Biocon Limited (IN:BIOCON)
:BIOCON
Want to see IN:BIOCON full AI Analyst Report?
BIOCON Stock Chart & Stats
₹364.20
₹0.80(0.22%)
At close: 4:00 PM EST
₹364.20
₹0.80(0.22%)
Day’s Range― - ―
52-Week Range₹327.75 - ₹436.80
Previous CloseN/A
Volume1.20M
Average Volume (3M)208.50K
Market Cap
₹696.72B
Enterprise Value₹710.72B
Total Cash (Recent Filing)₹64.69B
Total Debt (Recent Filing)₹165.35B
Price to Earnings (P/E)128.0
Beta0.85
Next Earnings
Aug 06, 2026EPS Estimate
0.49Next Dividend Ex-DateN/A
Dividend Yield0.12%
Share Statistics
EPS (TTM)4.01
Shares Outstanding1,620,907,700
10 Day Avg. Volume177,351
30 Day Avg. Volume208,504
Financial Highlights & Ratios
PEG Ratio-1.92
Price to Book (P/B)1.45
Price to Sales (P/S)2.92
P/FCF Ratio-94.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.09
Revenue Forecast (FY)₹200.66B
Bulls Say, Bears Say
Bulls Say
Diversified Biopharma Model & Manufacturing ScaleA multi-pronged business (biosimilars, biologics, APIs, CDMO and finished formulations) plus large-scale fermentation and biologics manufacturing provides durable revenue diversification and vertical integration. This supports scale economics, contract wins and resilience to single-product setbacks.
Consistent Multi-year Revenue GrowthSustained top-line expansion over multiple years creates a structural runway to fund R&D, maintain manufacturing utilization and support partnerships. Persistent revenue growth helps absorb cyclical pressure and enables reinvestment even if margins oscillate.
Improving Leverage And Capital StructureA materially lower debt-to-equity ratio reduces refinancing and solvency risk and preserves financial flexibility. Improved leverage supports longer-term investments in capacity and R&D, and makes the firm less vulnerable to interest-rate or funding shocks.
Bears Say
Sharp Margin CompressionA pronounced fall in gross and net margins is a structural concern: it reduces internal funds for R&D, capex and commercialization. If driven by cost inflation, pricing pressure or product-mix shifts, margin weakness can persist and limit sustainable profitability.
Weak Cash Generation And Negative Free Cash FlowNegative free cash flow and deteriorating operating cash conversion undermine funding flexibility for capex, capacity and M&A. Over months, this raises the probability of external financing, delayed projects, or tighter partnership terms, hindering strategic execution.
Very Low Return On EquityROE near 1% signals poor efficiency in converting capital into profits. Persistently low returns can constrain reinvestment, reduce shareholder support for dilutive funding, and indicate deeper issues around pricing, margins or capital allocation that impair long-term value creation.
Biocon Limited News
BIOCON FAQ
What was Biocon Limited’s price range in the past 12 months?
Biocon Limited lowest stock price was ₹327.75 and its highest was ₹436.80 in the past 12 months.
What is Biocon Limited’s market cap?
Biocon Limited’s market cap is ₹696.72B.
When is Biocon Limited’s upcoming earnings report date?
Biocon Limited’s upcoming earnings report date is Aug 06, 2026 which is in 74 days.
How were Biocon Limited’s earnings last quarter?
Biocon Limited released its earnings results on May 07, 2026. The company reported ₹1.27 earnings per share for the quarter, beating the consensus estimate of ₹1.174 by ₹0.096.
Is Biocon Limited overvalued?
According to Wall Street analysts Biocon Limited’s price is currently Overvalued.
Does Biocon Limited pay dividends?
Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Biocon Limited dividends here
What is Biocon Limited’s EPS estimate?
Biocon Limited’s EPS estimate is 0.49.
How many shares outstanding does Biocon Limited have?
Biocon Limited has 1,620,907,700 shares outstanding.
What happened to Biocon Limited’s price movement after its last earnings report?
Biocon Limited reported an EPS of ₹1.27 in its last earnings report, beating expectations of ₹1.174. Following the earnings report the stock price went up 0.486%.
Which hedge fund is a major shareholder of Biocon Limited?
Currently, no hedge funds are holding shares in IN:BIOCON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biocon Limited
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.
Technical Analysis
Blue Jet Healthcare Limited
―
Concord Biotech Ltd.
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―